Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Technology appraisal guidance
Reference number: TA391
Published: 25 May 2016
Last updated: 24 August 2016

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence

Review decision
Review decision – January 2019
Review decision paper (PDF 375 KB)

Published:

07 February 2019
Matrix of stakeholders (PDF 267 KB)

Published:

07 February 2019
Evaluation report
Appraisal consultation committee papers (PDF 4.72 MB)

Published:

25 May 2016
Final appraisal determination committee papers (PDF 610 KB)

Published:

25 May 2016